Skip to main content

Advertisement

Table 3 Reported hypoglycemia in study participants

From: Insulin lispro low mixture twice daily vs basal insulin glargine once daily and prandial insulin lispro once daily as insulin intensification strategies in patients with type 2 diabetes: Latin American subpopulation analysis of a randomized trial

Hypoglycemia LM25  (N = 80) IGL (N = 82)
Participants with ≥1 episode, n (%) Number of episodes per participant year, mean (SD) Participants with ≥1 episode, n (%) Number of episodes per participant year, mean (SD)
Overall (≤70 mg/dL) 57 (71.3) 18.9 (27.3) 56 (68.3) 21.6 (31.1)
Documented symptomatic (≤70 mg/dL) 45 (56.3) 9.6 (15.5) 40 (48.8) 11.0 (19.4)
Asymptomatic (≤70 mg/dL) 36 (45.0) 8.5 (17.9) 43 (52.4) 10.2 (20.9)
Nocturnal 24 (30.0) 2.4 (5.8) 22 (26.8) 2.8 (6.5)
Severe 1 (1.3) 0.1 (0.7) 0 (0) 0 (0)
  1. IGL once-daily basal insulin glargine plus once-daily prandial insulin lispro, LM25 75 % insulin lispro protamine suspension and 25 % insulin lispro solution, SD standard deviation